But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...

Dr Vinay Prasad has resigned from the FDA after less than three months amid controversy over Sarepta Therapeutics' gene ...

Shares of Sarepta Therapeutics ($SRPT) jumped over 14% on Tuesday after the FDA authorized the company to restart shipments ...

The gene therapy chief wanted to block fast-track drug approvals.

Gene Therapy Market Gene therapy market surges on breakthroughs in genome editing, rising chronic & genetic disease cases, regulatory appro ...

Alnylam Pharma raised its revenue outlook as its heart drug sees quick uptake.

The U.S. Food and Drug Administration's (FDA) top vaccine official is stepping down after just three months in a role that ...

Indian-origin scientist Vinay Prasad resigned as the FDA's vaccine and gene therapy chief in just three months after backlash ...

Tidmarsh will temporarily guide CBER’s regulatory activities while the FDA searches for a permanent department lead.

Other changes under Prasad, who was also the agency's chief medical and science officer, included a new policy limiting the ...

The Food and Drug Administration’s polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of ...

From the meme stock revival to Trump's Fed feud, Peter Hodson looks at some of the summer's more bizarre trends ...